Drug Type Small molecule drug |
Synonyms |
Target |
Action modulators |
Mechanism BSEP modulators(ATP binding cassette subfamily B member 11 modulators), MDR3 modulators(Multidrug resistance protein 3 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cholangitis, Sclerosing | Preclinical | United States | 01 Dec 2024 | |
Cholelithiasis | Preclinical | United States | 01 Dec 2024 | |
Nonalcoholic Steatohepatitis | Preclinical | United States | 01 Dec 2024 | |
Primary Biliary Cholangitis | Preclinical | United States | 01 Dec 2024 | |
progressive familial intrahepatic cholestasis | Preclinical | United States | 01 Dec 2024 |